Claims

Search the graph by meaning. Each result carries its current verdict; open one to see its decomposition, provenance, and the reasoning behind the assessment.

1 result

The IL-1β-blocking monoclonal antibody canakinumab: its cardiovascular outcomes evidence (notably the CANTOS trial), effects on inflammatory biomarkers such as CRP, safety (e.g., infection risk), and use in patients with residual inflammatory risk. Not for other anti-inflammatory agents unless directly compared.

In the CANTOS trial, canakinumab reduced recurrent cardiovascular events without lowering LDL cholesterol

VerifiedThe evidence, examined directly, establishes the claim.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Inflammation in atherosclerosis Atherosclerotic cardiovascular disease LDL cholesterolimportance · minorImportance 0.35, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →

Contribute

If a claim here is wrong, or missing evidence, open it: every claim page carries its own entry for challenges, evidence, and corrections. If the graph is missing a claim or a question entirely, propose it below. A proposal is reviewed on its wording; accepted proposals are matched against the graph before they enter it.